Results for tag: "Hemolytic Uremic Syndrome"

Hemolytic Uremic Syndrome (HUS) is a rare, life-threatening disorder that affects the blood, kidneys, and other organs. It is caused by the destruction of red blood cells, leading to anemia, kidney failure, and other complications. Treatment for HUS typically involves the use of hematological drugs, such as anticoagulants, immunosuppressants, and antibiotics. These drugs help to reduce the risk of further complications and improve the patient's quality of life. In addition, supportive care, such as dialysis and blood transfusions, may be necessary. The HUS market is a niche market, with a limited number of drugs available. However, the market is expected to grow in the coming years, as new treatments are developed and approved. Companies such as Pfizer, Novartis, and Sanofi are actively researching and developing new drugs for the treatment of HUS. Additionally, several biotechnology companies, such as Gilead Sciences and Celgene, are also involved in the development of new treatments. Show Less Read more